Search tips
Search criteria 


Logo of brjcancerBJC HomepageBJC Advance online publicationBJC Current IssueSubmitting an article to BJCWeb feeds
Br J Cancer. 1992 October; 66(4): 635–639.
PMCID: PMC1977431

Malignant progression of a mouse fibrosarcoma by host cells reactive to a foreign body (gelatin sponge).


The QR regressor tumour (QR-32), a fibrosarcoma which is unable to grow progressively in normal syngeneic C57BL/6 mice, was able to grow progressively in 13 out of 22 mice (59%) when it was subcutaneously coimplanted with gelatin sponge. We established four culture tumour lines from the resultant tumours (QRsP tumour lines). These QRsP tumour lines were able to grow progressively in mice even in the absence of gelatin sponge. The ability of QRsP tumour cells to colonise the lungs after intravenous injection and to produce high amounts of prostaglandin E2 (PGE2) during in vitro cell culture was much greater than that of parent QR-32 cells. These biological characteristics of QR-32 cells and QRsP tumour cells were found to be stable for at least 6 months when they were maintained in culture. We also observed that QR-32 cells were able to grow progressively in five out of 12 (42%) mice after coimplantation with plastic non-adherent peritoneal cells obtained from mice which had been intraperitoneally implanted with gelatin sponge. These host cells reactive to gelatin sponge increased the production of high amounts of PGE2 by QR-32 cells during 48 h coculture. Preliminary in vitro studies implicated the involvement of hydrogen peroxide and hydroxyl radical as some of the factors necessary to induce QR-32 cells to produce high amounts of PGE2 and to accelerate tumour progression.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.0M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Akporiaye ET, Saunders GC, Kraemer PM. A gelatin sponge model for studying tumor growth: quantitation of tumor cells and leukocytes in the CHO tumor. Experientia. 1987 Jun 15;43(6):589–593. [PubMed]
  • Akporiaye ET, Kudalore MK. Implantation of a gelatin-sponge as a model for effector recruitment. Tumor growth inhibition by T-lymphocytes recovered from a site of tumor rejection. Cancer Immunol Immunother. 1989;29(3):199–204. [PubMed]
  • Boone CW. Malignant hemangioendotheliomas produced by subcutaneous inoculation of Balb/3T3 cells attached to glass beads. Science. 1975 Apr 4;188(4183):68–70. [PubMed]
  • Boone CW, Takeichi N, Eaton SD, Paranjpe M. "Sontaneous" neoplastic transformation in vitro: a form of foreign body (smooth surface) tumorigenesis. Science. 1979 Apr 13;204(4389):177–179. [PubMed]
  • Fidler IJ, Kripke ML. Metastasis results from preexisting variant cells within a malignant tumor. Science. 1977 Aug 26;197(4306):893–895. [PubMed]
  • Fulton AM, Loveless SE, Heppner GH. Mutagenic activity of tumor-associated macrophages in Salmonella typhimurium strains TA98 and TA 100. Cancer Res. 1984 Oct;44(10):4308–4311. [PubMed]
  • Fulton A, Dorcey L, Heppner G. Host inflammatory cells and generation of tumor cell diversity. Adv Exp Med Biol. 1988;233:15–20. [PubMed]
  • Hanto DW, Hopt UT, Hoffman R, Simmons RL. Recruitment of unsensitized circulating lymphocytes to sites of allogeneic cellular interactions. Transplantation. 1982 May;33(5):541–546. [PubMed]
  • Ishikawa M, Okada F, Hamada J, Hosokawa M, Kobayashi H. Changes in the tumorigenic and metastatic properties of tumor cells treated with quercetin or 5-azacytidine. Int J Cancer. 1987 Mar 15;39(3):338–342. [PubMed]
  • Ishikawa M, Hosokawa M, Oh-hara N, Niho Y, Kobayashi H. Marked granulocytosis in C57BL/6 mice bearing a transplanted BMT-11 fibrosarcoma. J Natl Cancer Inst. 1987 Mar;78(3):567–571. [PubMed]
  • Loveless SE, Heppner GH. Tumor-associated macrophages of mouse mammary tumors. I. Differential cytotoxicity of macrophages from metastatic and nonmetastatic tumors. J Immunol. 1983 Oct;131(4):2074–2078. [PubMed]
  • Morikawa K, Walker SM, Jessup JM, Fidler IJ. In vivo selection of highly metastatic cells from surgical specimens of different primary human colon carcinomas implanted into nude mice. Cancer Res. 1988 Apr 1;48(7):1943–1948. [PubMed]
  • Okada F, Hosokawa M, Hasegawa J, Ishikawa M, Chiba I, Nakamura Y, Kobayashi H. Regression mechanisms of mouse fibrosarcoma cells after in vitro exposure to quercetin: diminution of tumorigenicity with a corresponding decrease in the production of prostaglandin E2. Cancer Immunol Immunother. 1990;31(6):358–364. [PubMed]
  • Sasaki Y, Imaoka S, Kasugai H, Fujita M, Kawamoto S, Ishiguro S, Kojima J, Ishikawa O, Ohigashi H, Furukawa H, et al. A new approach to chemoembolization therapy for hepatoma using ethiodized oil, cisplatin, and gelatin sponge. Cancer. 1987 Sep 15;60(6):1194–1203. [PubMed]
  • Shimamura Y, Gunvèn P, Takenaka Y, Shimizu H, Shima Y, Akimoto H, Arima K, Takahashi A, Kitaya T, Matsuyama T, et al. Combined peripheral and central chemoembolization of liver tumors. Experience with lipiodol-doxorubicin and gelatin sponge (L-TAE). Cancer. 1988 Jan 15;61(2):238–242. [PubMed]
  • Yamashina K, Miller BE, Heppner GH. Macrophage-mediated induction of drug-resistant variants in a mouse mammary tumor cell line. Cancer Res. 1986 May;46(5):2396–2401. [PubMed]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK